Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Science-backed ERA derivation by certified toxicologists with ex-agency experts -
Idelalisib
Drug Overview
What is Idelalisib?
Masuu Global provides end-to-end Environmental Risk Assessment (ERA) support for pharmaceutical and healthcare products, covering Phase I environmental exposure assessment, Phase II environmental fate and effects assessment, data-gap analysis, testing strategy, laboratory coordination and final regulatory-ready reporting.
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →ERA Phase I Evaluation, ERA Phase II Evaluation, Consortium Testing Support (OECD Ecotoxicology Study)
Regulatory Framework
Assessment Methodology
Masuu Global follows a science-based, tiered and risk-based ERA methodology, aligned with applicable international regulatory requirements. For human medicinal products, our approach is primarily guided by the EMA Guideline EMEA/CHMP/SWP/4447/00 Rev. 1, effective 1 September 2024, together with relevant OECD Test Guidelines and regional regulatory requirements.
EMA — Environmental Risk Assessment
Assessment of potential environmental exposure associated with the use, manufacture and disposal of medicinal products, with a structured approach to determine whether further environmental assessment is required.
Phase I — Environmental Exposure Assessment
Initial screening to determine potential environmental exposure, covering PEC calculation, physicochemical properties, usage and dosage data, environmental entry pathways, and persistence and fate considerations.
Phase II — Environmental Fate & Effects Assessment
Where Phase I indicates further assessment is required, Phase II provides detailed evaluation of environmental fate, persistence and ecological effects — including biodegradation, bioaccumulation, aquatic toxicity, PNEC derivation and PEC/PNEC risk characterisation.
OECD & International Testing Principles
Where laboratory studies are required, testing strategies are designed with consideration of relevant OECD Test Guidelines, GLP expectations and applicable regulatory requirements.
Risk-Based Environmental Assessment
Integration of physicochemical data, environmental fate information, ecotoxicological data, existing literature, published studies, regulatory databases, usage data, and environmental monitoring data.
Weight-of-Evidence (WoE) Approach
A scientifically justified WoE approach integrates existing data and avoids unnecessary testing wherever scientifically and regulatorily justified.
ERA Assessment Pathway
Phase I → Phase II → Risk Characterization
Each phase builds on the prior tier — screening first, escalating only when the evidence demands it.
Environmental Exposure Assessment
Initial screening to determine whether the substance requires progression to Phase II.
- Product and substance information review
- Indication, dose and usage assessment
- PEC calculation and environmental exposure estimation
- Physicochemical property review
- Initial environmental risk screening
- Determination of Phase II requirement
Environmental Fate & Effects
Detailed evaluation when Phase I triggers further assessment.
- Biodegradation, hydrolysis & photolysis
- Adsorption/desorption behaviour
- Bioaccumulation potential
- Algal, Daphnia and fish toxicity
- Chronic ecotoxicity, where required
- PEC/PNEC risk characterisation
Laboratory Coordination & Study Execution
When regulatory testing is mandatory, Masuu coordinates with qualified GLP/appropriate testing laboratories and specialized scientific partners — giving clients a single point of contact across the full testing lifecycle.
Final ERA Report — Contents
- Executive summary
- Substance & product information
- Environmental exposure assessment
- Phase I evaluation
- Phase II assessment (where applicable)
- Environmental fate assessment
- Ecotoxicological assessment
- PEC/PNEC calculations
- Risk characterisation
- Data gap evaluation
- Testing rationale
- Risk mitigation considerations
- References and supporting scientific evidence
How We Work
Report Preparation Process
Every ERA follows a structured, tiered workflow designed to deliver scientifically defensible and regulator-ready assessments.
Comprehensive Data Collection
Product, substance, usage, physicochemical, toxicological, environmental and regulatory information collected and reviewed.
Phase I Environmental Screening
Environmental exposure assessment and determination of whether the assessment can conclude at Phase I or requires progression.
Phase II Evaluation
Detailed environmental fate and ecotoxicological assessment when Phase II is triggered.
Data Gap & Testing Strategy
Missing information identified and available alternatives evaluated before recommending additional testing.
Consortium Testing Support
Where testing is mandatory, Masuu coordinates with qualified testing partners through its Consortium Model.
Scientific & Regulatory Review
Integration and critical review of generated and existing data by experienced scientific and regulatory experts.
Final ERA Delivery
Comprehensive ERA report with transparent methodology, scientific rationale, calculations, conclusions and regulatory recommendations.
Ex-Agency Advantage
Why Masuu Global?
Our experienced regulatory and scientific experts bring a practical regulatory perspective — helping clients understand not only what data are required, but why they are required and how regulators may evaluate them.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 7,000+ molecules.